United StatesIncluding Funding rounds, Bull / Bear thesis, Stock + earnings, Roster changes, Patents, News, and Open roles.
Already subscribed? Sign in →
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Apr 14, 2005 | IPO | $56.4M | — | Piper Jaffray |
| Jun 5, 2002 | Series C | $30M | — | RWI Group and Affiliates |
DexCom reported Q1 2026 revenue of $1.192 billion, up 15% year-over-year on a reported basis and 12% organically. GAAP operating income reached $255.3 million (21.4% margin), up 850 basis points from Q1 2025; GAAP net income was $199.5 million, or $0.51 per diluted share, versus $0.27 in the prior year. Gross margin improved to 62.9% from 56.9% year-over-year. The company expanded Dexcom G7 15-Day CGM distribution across all U.S. channels and introduced enhanced Smart Meal Logging features for its Stelo platform. For full-year 2026, DexCom raised guidance on non-GAAP operating margin and adjusted EBITDA margin while reiterating revenue guidance of $5.16–$5.25 billion (11–13% growth) and non-GAAP gross margin of 63–64%.
FY2026 revenue $5.16–$5.25B (11–13% growth); non-GAAP gross margin ~63–64%; non-GAAP operating margin ~23–23.5%; adjusted EBITDA margin ~31–31.5%
Co-founded DexCom in 1999 alongside Scott Glenn, John Burd, Lauren Otsuki, and Ellen Preston, building the company that would pioneer continuous glucose monitoring. Prior to DexCom, Megargel earned an MBA from Stanford University (1998) and focused on healthcare venture capital. He was also a co-founder of Avera Pharmaceuticals and held roles at Planet Biopharmaceuticals (Vice President), Windamere Venture Partners, and Mdedge. Megargel passed away in 2021 at age 52.
One of five co-founders of DexCom in 1999 alongside Scott Glenn, John Burd, Lauren Otsuki, and Bret Megargel. Prior to co-founding the continuous glucose monitor company, Preston built a career in medical device and healthcare sales and marketing spanning roughly 30 years, including roles at Johnson & Johnson — where she helped create a new product category and reshape pricing and delivery of contact lenses — and the Arizona Health Sciences Center (AHSC). She studied at Arizona State University. Her background in commercializing paradigm-changing medical products provided the commercial and market-facing expertise that complemented the scientific founders on the early DexCom team.
A biochemist by training (BS, Purdue; MS and PhD, University of...), Burd began his career at Miles Laboratories (Ames) in 1977, developing fluorescent immunoassays for diabetes diagnostics. That work laid the technical foundation for his co-founding DexCom in 1999, where as President and CEO he oversaw development of the first long-term implantable continuous glucose monitor. He holds roughly 35 patents and has authored 40+ publications. Post-DexCom, Burd founded Lysulin (2017), a nutritional supplement company targeting blood sugar management — extending his focus on diabetes beyond sensing into metabolic intervention.
Co-founded DexCom in 1999 alongside Scott Glenn, John Burd, Ellen Preston, and Bret Megargel, serving as a Vice President during the company's early years. Prior to DexCom, Otsuki founded a string of life-sciences ventures including SkinMedica (a clinical skincare company later acquired by Allergan) and Alastin Skincare. She also co-founded Prometheus Biosciences (now Prometheus Biosciences Inc.), NovaCardia, and Oncternal Therapeutics — collectively spanning dermatology, cardiovascular, oncology, and diagnostics. She holds a B.S. from the University of California, Davis. Across two decades, she has founded or co-founded five biotech firms, several of which reached public-market or acquisition exits.
Prior to co-founding DexCom in 1999, Glenn had already founded Prometheus Laboratories (1995) and Santarus (1996), and had been managing partner at Windamere Venture Partners since 1994 — a firm through which he pioneered a venture-company creation model that ultimately produced over two dozen life sciences startups. Earlier ventures included SkinMedica (acquired by Allergan) and, later, Zogenix, Somaxon Pharmaceuticals, and Evoke Pharma. He holds a B.S. from California State University and, after a five-year tenure as DexCom's chairman and founder, stepped away in 2004, well before the G4, G6, and G7 sensors made the company a CGM market leader.
Dexcom CEO discusses potential future applications for continuous glucose monitoring sensors at STAT Breakthrough Summit West.
DexCom adds two board directors through settlement with activist investor Elliott Management.
DexCom launches the G8, a next-generation continuous glucose monitor platform.
STAT Health Tech newsletter covers OpenAI policy positions and Dexcom continuous glucose monitor updates.
Dexcom G7 is the company's latest continuous glucose monitoring (CGM) system, featuring a fully integrated all-in-one sensor and transmitter worn on the upper arm. It delivers real-time glucose readings directly to a smartphone with a 30-minute warm-up — the shortest of any CGM on the market. The G7 supports 10-day wear (with a 15-day version available), is compatible with automated insulin delivery (AID) systems like Omnipod 5 and Tandem t:slim X2, and enables direct-to-Apple-Watch connectivity so users can view glucose data without carrying their phone. Its smaller, streamlined design and improved accuracy at the low end make it a top choice for people with Type 1 and Type 2 diabetes managing intensive insulin therapy.
Dexcom G6 is the previous-generation CGM system that set the standard for fingerstick-free diabetes management. It uses a two-piece design — a disposable sensor worn for 10 days and a reusable transmitter that lasts up to three months — to stream real-time glucose data to a smartphone or compatible receiver. The G6 requires no routine fingerstick calibration and offers customizable alerts for high and low glucose levels. It leads the industry in pump connectivity, integrating with multiple automated insulin delivery systems including Tandem, Omnipod, and Insulet devices, making it a reliable choice for users who need robust interoperability.
Stelo is Dexcom's over-the-counter (OTC) CGM launched in 2024, available without a prescription for adults with Type 2 diabetes who do not use insulin. It provides continuous glucose readings and insights directly to a smartphone app, helping users understand how food, activity, and daily routines affect their blood sugar. Stelo is designed for the broader wellness and prediabetes market — people who want to track their glucose patterns to make informed lifestyle adjustments. It uses the same sensor technology as Dexcom's prescription CGMs but is tailored with a simplified app experience focused on education and trend awareness rather than clinical alerts.
Abstract Disclosed are devices for determining an analyte concentration (e.g., glucose). The devices comprise a sensor configured to generate a signal associated with a concentration of an analyte and a sensing membrane located over the sensor. The sensing membrane comprises an enzyme layer, wherein the enzyme layer comprises an enzyme and a polymer comprising polyurethane and/or polyurea segments and one or more zwitterionic repeating units. The enzyme layer protects the enzyme and prevents it from leaching from the sensing membrane into a host or deactivating.
Abstract Multi-state engagement with continuous glucose monitoring (CGM) systems is described. Given the number of people that wear CGM systems and because CGM systems produce measurements continuously, a platform that provides a CGM system may have an enormous amount of data. This amount of data is practically, if not actually, impossible for humans to process. In implementations, a CGM platform includes a data analytics platform that obtains packages of glucose measurements provided by a CGM system and also obtains additional data associated with a user. The data analytics platform generates state information for the user by processing these CGM packages and the additional data, at least in part, by using one or more models. Based on this state information, the data analytics platform controls communication with the user, which may include generating intervention strategies to prevent users from transitioning to a negative state such as discontinuing use of the CGM system.
Abstract A device for generating alerts for Hypo and Hyperglycemia Prevention from Continuous Glucose Monitoring (CGM) determines a dynamic risk based on both information of glucose level and a trend obtainable from a CGM signals. The device includes a display whose color depends on the DR (for example, red for high DR, green for low risk). When DR exceeds a certain threshold, alerts are generated to suggest the patient to pay attention to the current glucose reading and to its trend, both of which are shown on the display in numbers and symbols (e.g. an arrow with different slope or color).
Machine learning in an artificial pancreas is described. An artificial pancreas system may include a wearable glucose monitoring device, an insulin delivery system, and a computing device. Broadly speaking, the wearable glucose monitoring device provides glucose measurements of a person continuously. The artificial pancreas algorithm, which may be implemented at the computing device, determines doses of insulin to deliver to the person based on a variety of aspects for the purpose of maintaining the person's glucose within a target range, as indicated by those glucose measurements. The insulin delivery system then delivers those determined doses to the person. As the artificial pancreas algorithm determines insulin doses for the person over time and effectiveness of the insulin doses to maintain the person's glucose level in the target range is observed, an underlying model of the artificial pancreas algorithm may be updated to better determine insulin doses.
Abstract Techniques and protocols for facilitating wireless secure communications between a sensor system and one or more other devices are disclosed. In certain embodiments, the techniques and protocols include secure proximity pairing techniques with reduced power. A method for pairing an analyte sensor system and one or more display devices includes broadcasting, from the analyte sensor system, for an initial connection, a low power general advertisement including an indication indicating the low power general advertisement is for proximity pairing. The method includes receiving, from a first display device, a connection request message in response to the low power general advertisement; performing an authentication procedure with the first display device; and pairing and bonding with the first display device based on successful authentication with the first display device.
An integrated system for the monitoring and treating diabetes is provided, including an integrated receiver/hand-held medicament injection pen, including electronics, for use with a continuous glucose sensor. In some embodiments, the receiver is configured to receive continuous glucose sensor data, to calculate a medicament therapy (e.g., via the integrated system electronics) and to automatically set a bolus dose of the integrated hand-held medicament injection pen, whereby the user can manually inject the bolus dose of medicament into the host. In some embodiments, the integrated receiver and hand-held medicament injection pen are integrally formed, while in other embodiments they are detachably connected and communicated via mutually engaging electrical contacts and/or via wireless communication.
Abstract User interfaces for glucose insight presentation are leveraged. A glucose monitoring application is configured to process glucose measurements to determine one or more glucose insights, e.g., about a user's glucose. The glucose measurements, for example, may be obtained from a glucose monitoring device that collects glucose measurements of the user at predetermined intervals, e.g., every five minutes. The glucose monitoring application configures a user interface, based on configuration data, to present one or more visual elements representative of the one or more glucose insights. For example, the glucose monitoring application may configure the user interface to include a visual element in the form of a color field which represents whether the user's current glucose measurement (e.g., the most recent glucose measurement obtained from the glucose monitoring device) is below, within, or above a glucose range.
Abstract Examples of invasive biosensor alignment and retention features and methods are described. One example biosensor includes a housing comprising: a first surface defining a first opening, and a second surface opposite the first surface, the second surface defining a second opening, the first and second openings defining a substantially unobstructed pathway through the housing; a biosensor wire partially disposed within the housing and having an exterior portion extending through the first opening; a hollow insertion needle positioned within the pathway and extending through the first opening, the hollow insertion needle at least partially encircling the biosensor wire; and a biosensor retention feature collapsible against the first surface of the housing, the biosensor retention feature encircling and contacting the hollow insertion needle.
We don't have a live feed for this company's ATS. Their careers page has every open role.
View all careers ↗